Tag: CAR-T
-
Latin America’s First Homegrown CAR-T Center Opens in Ribeirão Preto, Promising Lower Cancer Care Costs
Introduction: A Milestone for Latin America’s Public Health In a landmark move for Latin America, Ribeirão Preto welcomes the Nutera Center, the region’s first homegrown CAR-T (Chimeric Antigen Receptor T-cell) therapy program. Backed by significant public investment, the center aims to expand access to cutting-edge cancer treatment while driving down costs for Brazil’s public health…
-
Addressing Infection Risks: Immune Complications in CAR T-Cell and Bispecific Antibody Therapies for Advanced Multiple Myeloma
Understanding the Shift in Multiple Myeloma Treatment Advances in multiple myeloma (MM) have ushered in a new era of immunotherapies, notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. These approaches leverage the patient’s own immune system to target myeloma cells, often achieving deep and lasting responses where traditional therapies fall short.…